Alnylam Pharmaceuticals is up 6.4% today, likely driven by positive investor sentiment following the company's webinar held yesterday, March 24, which focused on its strategy for transforming ATTR amyloidosis care and expanding its TTR franchise. The stock is also benefiting from a strong broader biotech environment, as evidenced by significant gains in peers like SRPT and CORT, which suggests a sector-wide rotation into high-growth pharmaceutical names. While Morgan Stanley reiterated an Equalweight rating with a $360 price target earlier today, the move appears primarily supported by the ongoing momentum surrounding the company's revenue outlook and the market's favorable reception to the strategic updates provided during the recent investor event.
Click any event to see why ALNY moved that day
No significant catalyst events detected.